.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DH04_Doripenem.Doripenem

Information

Doripenem is a carbapenem-class beta-lactam antibiotic used in the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia including ventilator-associated pneumonia. Approved for use in several countries, its marketing authorization has been withdrawn in some regions, but it is still available and used in others.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers following intravenous infusion.

References

1. Roberts, JA, et al., & Lipman, J (2014). Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. The Journal of antimicrobial chemotherapy 69(9) 2508–2516. DOI:10.1093/jac/dku177 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24879665

2. Lee, DH, et al., & Kiem, S (2017). Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections. Antimicrobial agents and chemotherapy 61(5) –. DOI:10.1128/AAC.02185-16 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28223378

3. Wang, Y, et al., & Zhang, J (2022). Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations. Antibiotics (Basel, Switzerland) 11(7) –. DOI:10.3390/antibiotics11070958 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35884212

Revisions

• 06/2025 initial generated model